A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Latest Information Update: 05 Nov 2025
At a glance
- Drugs Sonelokimab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Registrational
- Sponsors MoonLake Immunotherapeutics
Most Recent Events
- 05 Nov 2025 New trial record